Last edition
News about "Neurocrine rare disease portfolio expansion"
Neurocrine to Acquire Soleno Therapeutics
Neurocrine to acquire Soleno Therapeutics, adding US FDA-approved VYKAT XR for Prader-Willi Syndrome and strengthening its rare disease and endocrinology portfolio.
Neurocrine Rare Disease Portfolio Expansion | 07/04/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members